U.S. BioDefense

US BioDefense, Inc. was a development-stage biotechnology company primarily focused on the biodefense sector, specializing in the detection and decontamination of biological threats. Founded in 2002 following increased national security concerns, the company aimed to develop rapid diagnostic kits for pathogens such as Anthrax, Ricin, and Botulinum toxin, as well as chemical solutions for environmental decontamination. The company was publicly traded on the OTC market under the ticker symbol UBDI. In 2009, the entity underwent a strategic pivot and changed its name to Entest BioMedical, Inc., shifting its focus toward veterinary oncology and stem cell research. During its operation as US BioDefense, it sought to provide critical infrastructure and safety tools for government agencies and first responders.